New stock news | Yino Pharmaceuticals submitted its application to the Hong Kong Stock Exchange for the third time. The cumulative loss during the reporting period was approximately 1.66 billion yuan.

According to the latest news from the Zhifang financial APP, it was revealed by the Hong Kong Stock Exchange on July 16th that Immvira Bioscience Inc. (hereinafter referred to as Yino Wei Pharmaceutical) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors.